Fate Therapeutics, Inc. (FATE)
- Previous Close
3.4500 - Open
3.5300 - Bid 3.4700 x 200
- Ask 3.5300 x 200
- Day's Range
3.3950 - 3.5550 - 52 Week Range
1.6300 - 8.8300 - Volume
726,071 - Avg. Volume
1,651,636 - Market Cap (intraday)
398.573M - Beta (5Y Monthly) 1.84
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7000 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.68
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
www.fatetherapeutics.comRecent News: FATE
View MorePerformance Overview: FATE
Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FATE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FATE
View MoreValuation Measures
Market Cap
398.57M
Enterprise Value
194.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
29.54
Price/Book (mrq)
1.00
Enterprise Value/Revenue
15.77
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.50%
Return on Equity (ttm)
-42.10%
Revenue (ttm)
12.32M
Net Income Avi to Common (ttm)
-175.72M
Diluted EPS (ttm)
-1.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
304.88M
Total Debt/Equity (mrq)
25.33%
Levered Free Cash Flow (ttm)
-66.67M